Gastric Cancer (Diagnosis)NCT07387237
Multigene Germline Panel Testing in Gastric Cancer Patients in Portugal
An observational study of Gastric Cancer (Diagnosis) and Stomach Cancer, run by Unidade Local De Saúde Do Norte Alentejano at 1 site in Portugal.
Trial summary
Multigene germeline panel test in gastric cancer patients Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastric Cancer (Diagnosis), Stomach Cancer
- How many people
- 51 participants
- Where
- 1 sitePortugal
- Study dates
- 20 Sep 2023to 1 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults (≥18 years) with histologically confirmed gastric adenocarcinoma who underwent MGPT between 2020 and 2025
Who may be able to join
- Eligible participants were adults (≥18 years) with histologically confirmed gastric adenocarcinoma who underwent MGPT between 2020 and 2025;
- Ability to understand Portuguese and/or English;
- Ability to provide valid informed consent.
Who cannot join
- All patients who met eligibility and inclusion criteria were included in the study;
- Patients without a definitive genetic report or with incomplete clinical data for key study variables were excluded.
Trial locations and contacts
1 site in 1 country.
About this study
Multigene germeline panel test in gastric cancer patients
Read the detailed description
We conducted a retrospective observational study including 51 patients with histologically confirmed gastric cancer who underwent MGPT between 2020 and 2025. Genetic testing was performed using validated 15 or 30 gene panels. Clinical, pathological, and survival data were retrieved from medical records.
- Conditions
- Gastric Cancer (Diagnosis), Stomach Cancer
- Keywords
- Multigene Germeline Panel Test, Gastric Cancer
- Medical subject headings
- Stomach Neoplasms, Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
MGPT result
positive vs negative
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2026
- Study start20 Sep 2023
- Primary completion1 Aug 2025
- Study completion1 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gastric Cancer (Diagnosis)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- Unidade Local De Saúde Do Norte Alentejano
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Beatriz Mourato, Unidade Local De Saúde Do Norte Alentejano
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07387237
- Sponsor's protocol ID
- MGPT Gastric Cancer
- Other IDs
- MGPT Gastric Cancer
- Status last verified
- Jan 2026
- First submitted
- 1 Oct 2025
- Last updated
- 4 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Mourato B, Cordeiro B, Costa Pinto F, Pratas N, Fronteira I, Areia M, Dinis R. Multigene Germline Panel Testing in Gastric Cancer Patients in a Portuguese Population. Cancer Med. 2026 Mar;15(3):e71732. doi: 10.1002/cam4.71732.
PubMed 41853923
Study at a glance
From the registry record, last updated by the sponsor on 4 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multigene Germline Panel Testing in Gastric Cancer Patients in Portugal
- ClinicalTrials.gov ID
- NCT07387237
- Acronym / sponsor ID
- MGPT Gastric Cancer
- Conditions
- Gastric Cancer (Diagnosis), Stomach Cancer
- Keywords
- Multigene Germeline Panel Test, Gastric Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 51 participants (actual)
- Lead sponsor
- Unidade Local De Saúde Do Norte AlentejanoUniversity, hospital or other
- Study start
- 20 Sep 2023 (actual)
- Primary completion
- 1 Aug 2025 (actual)
- Study completion
- 1 Sep 2025 (actual)
- First posted
- 4 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multigene germeline panel test in gastric cancer patients
Detailed description
We conducted a retrospective observational study including 51 patients with histologically confirmed gastric cancer who underwent MGPT between 2020 and 2025. Genetic testing was performed using validated 15 or 30 gene panels. Clinical, pathological, and survival data were retrieved from medical records.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults (≥18 years) with histologically confirmed gastric adenocarcinoma who underwent MGPT between 2020 and 2025
Key inclusion criteria (3 listed)
- Eligible participants were adults (≥18 years) with histologically confirmed gastric adenocarcinoma who underwent MGPT between 2020 and 2025;
- Ability to understand Portuguese and/or English;
- Ability to provide valid informed consent.
Key exclusion criteria (2 listed)
- All patients who met eligibility and inclusion criteria were included in the study;
- Patients without a definitive genetic report or with incomplete clinical data for key study variables were excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
MGPT result
Time frame: 5 years
positive vs negative
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Feb 2026.
- Derived from this study: PubMed 41853923Mourato B, Cordeiro B, Costa Pinto F, Pratas N, Fronteira I, Areia M, Dinis R. Multigene Germline Panel Testing in Gastric Cancer Patients in a Portuguese Population. Cancer Med. 2026 Mar;15(3):e71732. doi: 10.1002/cam4.71732.
- Individual participant dataSharing planned: Yes
Related trials for Gastric Cancer (Diagnosis)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Cancer (Diagnosis) and Stomach Cancer, run by Unidade Local De Saúde Do Norte Alentejano at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MGPT result (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07387237, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2026.